Actively Recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Led by Jinling Hospital, China · Updated on 2025-12-05
39
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
CONDITIONS
Official Title
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects have fully understood and voluntarily signed the informed consent form (ICF)
- Aged 18 to 80 years at the time of signing the informed consent
- Both men and women are eligible
- ECOG performance status score of 0-1
- Histologically or cytopathologically confirmed renal cell carcinoma with clear cell components, including unresectable or recurrent metastatic cases
- Presence of measurable targets according to RECIST version 1.1
- Well-functioning major organs
You will not qualify if you...
- History of other malignancies within the past 5 years except certain treated cancers expected to be cured
- Systemic treatment with other antitumor agents, local therapy, or investigational drugs within 4 weeks prior to study
- Major surgery within 4 weeks prior to study dosing or still recovering
- History of severe drug allergies including antibody drugs
- Contraindications to restarting immunotherapy
- History of allogeneic organ or hematopoietic stem cell transplantation requiring long-term corticosteroids
- Unresolved toxicities from previous antitumor therapies except specified exceptions
- Presence of central nervous system metastases or cancerous meningitis
- Clinically significant liver disease or active viral hepatitis
- Uncontrolled fluid buildup requiring repeated drainage
- Severe or uncontrolled diseases
- Renal failure requiring dialysis
- Active or suspected autoimmune diseases
- Live attenuated vaccine within 4 weeks prior to study or expected during study
- History of psychotropic drug abuse or mental disorders
- Other severe medical, psychiatric conditions, or lab abnormalities increasing study risks or affecting results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jinling Hospital
Nanjing, Jiangsu, China, 401520
Actively Recruiting
Research Team
L
Le Qu, M. D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here